COMMUNIQUÉS West-GlobeNewswire

Conavi Medical Highlights Peer-Reviewed Publication Demonstrating Advantages of Hybrid IVUS-OCT Imaging
13/02/2026
- New Academic Data Supports Clinical and Commercial Value of Hybrid Imaging Platform- TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (“Conavi” or the “Company”), a leader in hybrid intravascular [...]
Medicenna Announces Changes to Board Composition
13/02/2026
TORONTO and HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of [...]
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
13/02/2026
- Cash position of US$195 million as of December 31, 2025, before adjustment for post quarter events - - Topline data readout from the Phase 2 study evaluating HLP004 in generalized anxiety disorder (“GAD”) expected in [...]
Nasus Pharma Announces Closing of $15.0 Million Private Placement
13/02/2026
TEL AVIV, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today [...]
Invitation to the presentation of ALK’s annual report 2025 on Friday, 20 February 2026
13/02/2026
ALK ( ALKB:DC / OMX: ALK B ) will publish its annual report for 2025 in the morning on Friday, 20 February 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, [...]
Sienna Announces February Dividend
13/02/2026
MARKHAM, Ontario, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
13/02/2026
Medicenna to present updated internal and external data sets related to bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit to be held in Boston from 17-19 February 2026 Updated ABILITY-1 clinical data [...]
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
13/02/2026
PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on [...]
Profusa and Mayo Clinic collaborate to Advance High-Impact Clinical Applications of Oxygen Monitoring Technologies
13/02/2026
Collaboration with Mayo Clinic aims to accelerate regulatory approval and commercialization of Lumee™ wearable continuous tissue oxygen monitoring product Seeking to develop and commercialize new tethered continuous [...]
Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
13/02/2026
Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 2026 revenue guidance of $8-10 million $22.3 million pro forma cash, cash equivalents, restricted cash and marketable [...]
Moleculin Launches CEO Corner Platform to Share Strategic Insights
13/02/2026
CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company by submitting [...]
Opus Genetics Announces $25 Million Private Placement
13/02/2026
RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Nxera Pharma Proposes Changes to its Board of Directors
13/02/2026
Mr. Takeo Morooka nominated for appointment as new External Director Ms. Miwa Seki and Mr. Noriaki Nagai to retire from the Board of Directors Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“ [...]
EssilorLuxottica announces the launch of a share buyback program
13/02/2026
EssilorLuxottica announces the launch of a share buyback program Paris, France (13 February 2026 – 8:00am) – EssilorLuxottica announces the launch of a share buyback program, reflecting the Group’s confidence in its [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025
13/02/2026
Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and [...]
Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy
13/02/2026
In ALIGN study, Vanrafia (atrasentan) showed positive difference in eGFR change from baseline vs. placebo at Week 136, 4 weeks after study treatment ended 1 Results favored Vanrafia across multiple timepoints, measures [...]
EssilorLuxottica annonce le lancement d’un programme de rachat d’actions
13/02/2026
EssilorLuxottica annonce le lancement d’un programme de rachat d’actions Paris, France (13 février 2026 – 8h00) – EssilorLuxottica annonce le lancement d’un programme de rachat d’actions qui traduit la confiance du [...]
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
13/02/2026
LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Coherus Oncology, Inc. Announces Pricing of Public Offering of Common Stock
13/02/2026
REDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (“Coherus” or the “Company”) (NASDAQ: CHRS), today announced the pricing of an underwritten public offering of 28,600,000 shares of the [...]

Pages